Previous 10 | Next 10 |
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00...
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspheres (R064766) Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy...
2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...
2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...
2024-04-04 09:21:23 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Pos...
Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience's global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline ...
2024-04-03 08:28:03 ET More on Teva , UroGen Pharma, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns UroGen: All Eyes On UGN-102 UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript Teva and Viatris revives chance to dispute J&J's ...
2024-04-01 12:17:16 ET NYSE: TEVA NASDAQ: VTRS NYSE: JNJ More on Johnson & Johnson, Teva Pharmaceutical, etc. Viatris Stock Is Still Worth Buying With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Viatris Inc. (VTRS) R&...
2024-04-01 09:05:12 ET More on Carlyle, Teva Pharmaceutical, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns Carlyle Group: A Strong Company But Trades At A Premium Carlyle: Asset-Management Tailwinds And A High Yield Carlyle Group names Lin...
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide ...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...